Overview

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Treatments:
3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine
Midazolam
Rosiglitazone
Warfarin